Posted on

PharmAla Biotech & SABI Mind Announce MDMA Supply Agreement

PharmAla Biotech & SABI Mind Announce MDMA Supply Agreement

PharmAla to supply SABI Mind’s Healing Centres, subject to Health Canada approval

VANCOUVER, May 19, 2022 (Canada Newswire) – PharmAla Biotech (CSE:MDMA) is pleased to announce that it has signed an agreement with SABI Mind Inc. which will allow for its GMP MDMA to be administered to patients at SABI Mind’s Healing Centres. SABI Mind is a leading and rapidly growing psychedelic clinic and research organization that provides psychedelic-assisted therapies in Calgary and at upcoming locations in Edmonton and Victoria.

“We’re very pleased to announce this supply agreement with PharmAla to increase access to psychedelic-assisted therapies for patients in need”, says Philippe Lucas PhD, President at SABI Mind. “Research has shown MDMA to be a safe and effective treatment for PTSD, end of life anxiety, and other treatment-resistant mental health issues, and our clinical team is looking forward to working with patients, Health Canada and the highly qualified team at PharmAla to provide MDMA-based treatments to authorized patients.”

Through this agreement, PharmAla will provide GMP, clinical-grade MDMA to SABI Mind, subject to regulatory approval. The MDMA will come from PharmAla’s GMP MDMA value chain, the first to be established in North America. As part of the agreement, PharmAla will have a right to access anonymized patient data collected during treatment by SABI Mind.

“I have long respected SABI and their principals for operating at high ethical and regulatory standards. Their work on developing the Canadian Psychedelic Survey prove that they are true academic leaders in the psychedelics industry,” said Nick Kadysh, PharmAla’s CEO. “As such, I think this is a natural partnership for both of our companies, and should allow for SABI Mind to expand their current offerings of psychedelic-assisted therapies.”

For more information, please visit www.PharmAla.ca, where you can sign up to receive regular new updates.

ABOUT PHARMALA

PharmAla Biotech Holdings Inc. (CSE: MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials, and to develop novel drugs in the same class. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. Our team of dedicated professionals includes regulatory experts, scientists, and biomanufacturing professionals. PharmAla has built what it believes to be North America’s first cGMP MDMA value chain, encompassing GMP manufacturing of Active Pharmaceutical Ingredient (API), and drug product formulation. PharmAla’s research and development unit has also begun preclinical research into two patented Novel Chemical Entities (NCEs) based on MDXX class molecules, with proof-of-concept research currently ongoing at the University of Arkansas Medical School.

Posted on

SABI Mind and Reverie Psychedelics Partner To Expand Research Into Psychedelic-Assisted Therapies

SABI Mind and Reverie Psychedelics Partner To Expand Research Into Psychedelic-Assisted Therapies

CALGARY, AB, March 31, 2022 /CNW/ – SABI Mind (SABI), an Alberta-based psychedelic therapy clinic group that provides treatments for mental health and chronic pain, is pleased to announce Canada’s first research partnership with U.S. based Reverie Psychedelics (Reverie). A leading and rapidly growing psychedelic clinic and research organization that coordinates clinical trials and associated partnerships between psychedelic companies and clinical sites. This collaboration will provide academics and psychedelic companies researching psychedelic therapies access to SABI clinics, qualified clinical staff, and Reverie’s expanding suite of clinical trial support services as these novel treatments work their way through the rigorous drug development process.

“I am elated to have the opportunity to work alongside the outstanding team and research-experienced physicians and staff at SABI,” said Robert Wallace, Founder and CEO of Reverie. “This is our first Canadian clinical research partnership and will provide researchers from Canada, the U.S. and around the globe with qualified clinical trial sites and SABI patients with access to emerging psychedelic treatment options.”

Having developed and coordinated the Canadian Psychedelic Survey (CPS), SABI has already established itself as an academic leader in the psychedelic treatment space. This collaboration with Reverie will support and expand SABI’s clinical trial goals.

“This is the dawn of the Renaissance in psychedelic drug research and development,” says Philippe Lucas, Ph.D., President of SABI Mind. “Dozens of companies and academic institutions are developing psychedelic medicines, and SABI is pleased to partner with the skilled and experienced team at Reverie to support research into psychedelic-based treatments and expand our understanding of how they might improve the health and quality of life of chronically ill patients.”

About Sabi Mind, Inc.
SABI Mind is a Calgary-based clinic group supporting the careful mending of mental health and chronic pain through psychedelic-assisted therapies. SABI Mind empowers those discouraged by the conventional treatment methods with a patient-centred model supported by experienced psychiatrists, anesthesiologists, therapists, client experience specialists, and other clinic staff specially trained in ketamine-assisted psychotherapy. Find out more at www.sabimind.com.

About Reverie Psychedelics
Reverie Psychedelics (Reverie) is a leading and rapidly growing psychedelic-assisted psychotherapy clinic and research organization. Reverie’s clinics are structured to provide qualified individuals access to psychedelic therapies, special access programs, and clinical trials focused on psychedelic-based treatments. Find out more at www.reveriepsychedelics.com.

SOURCE SABI Mind

Cision
Cision

View original content: http://www.newswire.ca/en/releases/archive/March2022/31/c9788.html